Procrit, Gemzar, Camptosar At Risk Under 2005 Medicare Payment Rates, ASCO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
CMS estimates the total drop in Medicare payment reductions for 2005 at 8%; an ASCO survey of community clinics found a 15% payment reduction. ASCO seeks legislation establishing a floor in total payments through 2006.
You may also be interested in...
Aranesp Performance Strong Heading Into "Transition" Time, Amgen Says
The company is talking with oncologists about Aranesp ahead of a switch in Medicare reimbursement in January 2005. U.S. sales for the red blood cell product were up 32% in the third quarter.
Aranesp Performance Strong Heading Into "Transition" Time, Amgen Says
The company is talking with oncologists about Aranesp ahead of a switch in Medicare reimbursement in January 2005. U.S. sales for the red blood cell product were up 32% in the third quarter.
Price Competition To Procrit Is Beginning To Stabilize, J&J Says
Recent price increases for both Procrit and Amgen’s Aranesp indicate the discount war may be over for now, J&J says. The company remains positive about the impact of the 2005 changes to Medicare Part B drug reimbursement on Procrit’s positioning within the EPO market.